Abstract Treatment outcomes for major depressive disorder (MDD) need to be improved.
Presently, no clinically relevant tools have been established for stratifying subgroups or …

Objectives: The overview outlines two decades of research from the European Group for the
Study of Resistant Depression (GSRD) that fundamentally impacted evidence-based …

BackgroundSuicide attempt (SA), which is one of the strongest predictors of completed
suicide, is common in major depressive disorder (MDD) but its prevalence across …

Background Several studies indicate that ketamine has rapid antidepressant effects in
patients with treatment-resistant depression (TRD). The extent to which repeated doses of …

BackgroundMajor depressive disorder (MDD) is a highly heterogeneous condition in terms
of symptom presentation and, likely, underlying pathophysiology. Accordingly, it is possible …

Background Clear guidance for successive antidepressant pharmacological treatments for
non-responders in major depression is not well established. Method Based on the …

Objectives Clinical variables were investigated in the 'treatment resistant depression (TRD)‐
III'sample to replicate earlier findings by the European research consortium 'Group for the …

We performed a retrospective, case-control study in consecutive ischemic stroke patients
admitted to our stroke rehabilitation unit. Patients were matched for severity of neurological …

A theoretical framework is proposed to gain insight into the pathogenesis of major
depressive disorder (MDD). Despite being a relatively weak argument, the neurogenesis …

There is considerable diversity in how treatment-resistant depression (TRD) is defined.
However, every definition incorporates the concept that patients with TRD have not …